⌘K
Loading ticker…
As of 2026-08-24, Cellectar Biosciences INC NEW (CLRB) has a 3-month relative strength percentile of 19 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 41. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.0%, relative volume 0.56×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
CLRB is in a stage 4 downtrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -2.1% / -15.2%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
CLRB is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $129K notional.
Held by 2 ETFs · $208K across latest filings · largest weight 0.00% (VXF).
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $129K | — |
| VXFVanguard Extended Market ETF | 0.00% | $79K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CLRB Jan avg: 5.67% median: -1.27% win: 50% σ: 26.07% n: 4 2022-04-12 → 2026-07-31 | CLRB Feb avg: 4.88% median: 2.04% win: 100% σ: 6.98% n: 4 2022-04-12 → 2026-07-31 | CLRB Mar avg: -4.90% median: -3.40% win: 50% σ: 13.25% n: 4 2022-04-12 → 2026-07-31 | CLRB Apr avg: -8.67% median: -10.86% win: 40% σ: 13.37% n: 5 2022-04-12 → 2026-07-31 | CLRB May avg: 0.01% median: 1.30% win: 60% σ: 15.66% n: 5 2022-04-12 → 2026-07-31 | CLRB Jun avg: -2.83% median: -7.06% win: 20% σ: 16.83% n: 5 2022-04-12 → 2026-07-31 | CLRB Jul avg: -11.28% median: -7.55% win: 0% σ: 12.70% n: 5 2022-04-12 → 2026-07-31 | CLRB Aug avg: 8.40% median: 1.47% win: 75% σ: 21.61% n: 4 2022-04-12 → 2026-07-31 (current) | CLRB Sep avg: 5.67% median: 6.13% win: 50% σ: 36.60% n: 4 2022-04-12 → 2026-07-31 | CLRB Oct avg: -23.09% median: -23.90% win: 0% σ: 19.21% n: 4 2022-04-12 → 2026-07-31 | CLRB Nov avg: -5.87% median: -2.43% win: 50% σ: 13.54% n: 4 2022-04-12 → 2026-07-31 | CLRB Dec avg: -23.83% median: -13.44% win: 25% σ: 39.88% n: 4 2022-04-12 → 2026-07-31 |